

## Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission

\*Emmanuel Ifeanyi Obeagu<sup>1</sup> and Getrude Uzoma Obeagu<sup>2</sup>

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda

<sup>2</sup>School of Nursing Science, Kampala International University, Uganda

\*Corresponding authour: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

### Abstract

Early infant diagnosis (EID) plays a pivotal role in the global efforts to halt the transmission of HIV, particularly in pediatric populations. With an estimated 150,000 children newly infected with HIV in 2020, the urgency to diagnose and treat HIV-infected infants is paramount. This paper explores the significance of early infant diagnosis in the context of preventing mother-to-child transmission (PMTCT) of HIV, the current challenges faced, and potential strategies to enhance EID programs. It emphasizes the critical role of EID in initiating timely antiretroviral therapy (ART), improving infant survival rates, and reducing HIV transmission rates. Furthermore, the review discusses emerging technologies and innovations that hold promise for enhancing EID accessibility, accuracy, and efficiency. Overall, early infant diagnosis stands as a cornerstone in the global fight against HIV/AIDS, highlighting the necessity for continued investment, innovation, and integration within comprehensive HIV/AIDS prevention and treatment programs.

**Keywords:** *Early Infant Diagnosis, HIV Transmission, Pediatrics, Antiretroviral Therapy, Prevention of Mother-to-Child Transmission (PMTCT), Public Health*

### Introduction

Early infant diagnosis (EID) represents a cornerstone in the global endeavor to combat the spread of HIV/AIDS, particularly among vulnerable pediatric populations. With approximately 150,000 children newly infected with HIV in 2020, the urgency to implement effective EID programs has never been more pressing. EID involves the timely testing of infants born to HIV-positive mothers, enabling the prompt initiation of antiretroviral therapy (ART) if necessary. This proactive approach not only improves infant survival rates but also plays a crucial role in preventing further

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. Elite Journal of Health Science, 2023; 1(1):1-11

transmission of the virus. As such, understanding the significance of EID in the context of preventing mother-to-child transmission (PMTCT) of HIV is paramount. The importance of EID extends beyond individual health outcomes, contributing significantly to public health initiatives aimed at curbing the global HIV epidemic. Timely diagnosis allows for the early identification of HIV-infected infants, enabling them to access life-saving treatment and care. Furthermore, by reducing the viral load in HIV-positive infants through ART, EID programs help mitigate the risk of onward transmission, thus safeguarding future generations from the devastating effects of HIV/AIDS. Consequently, EID serves as a pivotal strategy in achieving the ambitious targets set forth by global initiatives such as UNAIDS' 95-95-95 goals.<sup>1-20</sup>

Despite the clear benefits of EID, numerous challenges persist in ensuring universal access to testing services, particularly in resource-limited settings. These challenges include inadequate healthcare infrastructure, limited availability of diagnostic technologies, and social stigma surrounding HIV/AIDS. Additionally, logistical barriers such as sample transportation and laboratory processing times can delay the delivery of test results, further hindering the effectiveness of EID programs. Addressing these challenges requires a multifaceted approach that encompasses both technological innovation and structural reform within healthcare systems. In recent years, significant strides have been made in advancing EID technologies and strategies to overcome existing barriers. Innovations such as point-of-care testing devices and dried blood spot (DBS) sampling have emerged as promising solutions to enhance the accessibility and efficiency of EID services, particularly in remote or resource-limited settings. Furthermore, the integration of telemedicine and mobile health interventions holds potential for expanding access to EID and providing remote support to healthcare providers. By harnessing these innovations and fostering collaboration between stakeholders, EID programs can be strengthened to achieve greater impact in the fight against HIV/AIDS.<sup>21-35</sup>

### **Importance of Early Infant Diagnosis in Halting HIV Transmission**

The importance of early infant diagnosis (EID) in halting HIV transmission cannot be overstated. EID serves as a critical intervention in the prevention of mother-to-child transmission (PMTCT) of HIV, a process that can occur during pregnancy, childbirth, or breastfeeding. Without timely diagnosis and treatment, HIV-infected infants face a significantly higher risk of morbidity and mortality. Moreover, untreated infants can continue to transmit the virus to others, perpetuating the cycle of HIV transmission within communities. Timely identification of HIV infection through EID enables prompt initiation of antiretroviral therapy (ART) in infants, which is essential for suppressing the virus and preventing disease progression. ART not only improves the health outcomes of HIV-infected infants but also reduces their risk of transmitting the virus to others. By initiating treatment early in life, EID programs contribute to reducing infant mortality rates and improving overall child survival. Furthermore, EID plays a crucial role in breaking the chain of HIV transmission from mother to child. Infants born to HIV-positive mothers are at risk of acquiring the virus during pregnancy, childbirth, or breastfeeding. However, with timely diagnosis and initiation of ART, the risk of mother-to-child transmission can be significantly reduced. EID programs thus serve as a vital component of PMTCT strategies, helping to achieve the ambitious targets set forth by global initiatives such as UNAIDS' 95-95-95 goals. In addition to its impact on

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. *Elite Journal of Health Science*, 2023; 1(1):1-11

individual health outcomes, EID has broader implications for public health. By identifying HIV-infected infants early in life, EID programs help to prevent the spread of the virus within communities. Infants who receive early treatment are less likely to transmit HIV to their peers or future partners, thereby reducing the overall burden of HIV/AIDS on society. Despite its significance, EID programs face challenges that hinder their effectiveness. These challenges include limited access to testing services, particularly in remote or resource-limited settings, as well as social stigma surrounding HIV/AIDS. Additionally, logistical barriers such as sample transportation and laboratory processing times can delay the delivery of test results, further hindering the impact of EID programs.<sup>36-62</sup>

### **Challenges in Early Infant Diagnosis**

In many resource-limited settings, access to EID testing services is limited due to inadequate healthcare infrastructure, shortages of trained personnel, and geographical barriers.<sup>63</sup> Remote and rural areas often lack the necessary laboratory facilities and equipment for conducting diagnostic tests, making it difficult for HIV-exposed infants to access timely screening. Logistical challenges such as sample transportation and laboratory processing times can result in delays in delivering test results to healthcare providers and caregivers. These delays can impede the timely initiation of antiretroviral therapy (ART) for HIV-infected infants, leading to missed opportunities for preventing disease progression and reducing transmission rates. The current standard of care for EID involves polymerase chain reaction (PCR) testing, which requires specialized equipment and technical expertise. Performing PCR tests in resource-limited settings can be logistically challenging and costly, particularly in settings where infrastructure and trained personnel are lacking. Additionally, the complexity of PCR testing may result in errors or false-negative results, leading to missed diagnoses or delayed treatment initiation. Stigma surrounding HIV/AIDS remains a significant barrier to EID, particularly in communities where HIV-related discrimination and prejudice are prevalent.<sup>64</sup> Fear of disclosure and social ostracization may deter caregivers from seeking EID testing for their infants or adhering to treatment recommendations. Addressing social and cultural barriers requires targeted community engagement and education efforts to promote awareness, acceptance, and uptake of EID services. EID services are often fragmented and poorly integrated within healthcare systems, leading to gaps in care and missed opportunities for early diagnosis and treatment. Improving integration between maternal and child health services, HIV testing and treatment programs, and pediatric care can enhance the continuity of care for HIV-exposed infants and facilitate timely access to EID testing and treatment.

### **Strategies to Enhance Early Infant Diagnosis Programs**

Investing in healthcare infrastructure, particularly in resource-limited settings, is essential for expanding access to EID services.<sup>63</sup> This includes improving laboratory facilities, procuring necessary equipment and supplies, and training healthcare personnel in EID testing and management. Point-of-care testing devices enable rapid, on-site diagnosis of HIV infection, eliminating the need for sample transportation and reducing turnaround times for test results. Integrating POCT technologies into EID programs can facilitate timely diagnosis and treatment initiation, particularly in remote or underserved areas. Building laboratory capacity for conducting

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. *Elite Journal of Health Science*, 2023; 1(1):1-11

polymerase chain reaction (PCR) testing and other diagnostic assays is crucial for ensuring the accuracy and reliability of EID test results. This includes establishing quality assurance programs, implementing standardized testing protocols, and providing ongoing training and support to laboratory personnel.<sup>64</sup> Enhancing access to EID services requires adopting a multi-pronged approach that addresses geographical, financial, and social barriers. This may involve establishing mobile testing units, conducting outreach and community-based testing initiatives, integrating EID services with maternal and child health programs, and providing financial assistance or incentives to caregivers for seeking testing and treatment for their infants. Healthcare providers play a critical role in promoting early testing and linkage to care for HIV-exposed infants. Providing comprehensive training on EID guidelines, testing procedures, and treatment protocols can empower providers to identify and manage HIV-infected infants effectively. Additionally, raising awareness among healthcare workers and caregivers about the importance of EID and the benefits of early diagnosis and treatment is essential for increasing uptake of EID services. Harnessing technology and innovation can enhance the efficiency and effectiveness of EID programs. This includes deploying telemedicine and mobile health interventions for remote monitoring and support, implementing electronic medical record systems for tracking patient data and test results, and exploring novel diagnostic technologies such as dried blood spot (DBS) sampling and nucleic acid amplification tests (NAATs) for improving accessibility and accuracy of EID testing.

### **Emerging Technologies and Innovations**

Emerging technologies and innovations hold promise for revolutionizing early infant diagnosis (EID) programs, making them more accessible, accurate, and efficient. POCT devices enable rapid, on-site testing for HIV infection, eliminating the need for sample transportation and reducing turnaround times for test results.<sup>65</sup> These portable devices can be deployed in remote or resource-limited settings, enabling healthcare providers to diagnose HIV-infected infants quickly and initiate treatment without delay. Dried Blood Spot (DBS) Sampling involves collecting a small volume of blood onto filter paper, which can be easily transported and stored at room temperature. DBS samples are stable for extended periods, making them ideal for remote or resource-limited settings where access to cold chain storage may be limited. DBS sampling offers a convenient and cost-effective alternative to traditional venous blood collection for EID testing. Nucleic Acid Amplification Tests (NAATs) are highly sensitive molecular diagnostic assays that amplify and detect the genetic material of HIV in infant blood samples.<sup>66</sup> These tests offer superior sensitivity and specificity compared to conventional PCR testing, enabling earlier detection of HIV infection in infants. NAATs can also be performed on DBS samples, further enhancing their utility for EID testing in resource-limited settings. Telemedicine and mHealth interventions leverage mobile technology and digital platforms to provide remote consultation, monitoring, and support for EID programs. These interventions enable healthcare providers to access expert guidance, share diagnostic information, and communicate with caregivers in real-time, regardless of geographic location. Telemedicine and mHealth platforms can improve the efficiency and effectiveness of EID services, particularly in areas with limited access to healthcare resources. Electronic Medical Record (EMR) Systems facilitate the electronic documentation, storage, and retrieval of patient

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. *Elite Journal of Health Science*, 2023; 1(1):1-11

data and test results, streamlining EID program management and improving data accuracy and accessibility. EMR systems enable healthcare providers to track patient progress, monitor treatment outcomes, and generate real-time reports for program monitoring and evaluation. By digitizing EID data and integrating with existing health information systems, EMR systems can enhance the coordination and continuity of care for HIV-infected infants.

## Conclusion

Early infant diagnosis (EID) stands as a critical intervention in the global fight against HIV/AIDS, particularly in pediatric populations. EID programs play a pivotal role in preventing mother-to-child transmission of HIV, improving infant survival rates, and reducing the overall burden of HIV/AIDS on society. However, despite significant progress in recent years, EID programs continue to face challenges that hinder their effectiveness, including limited access to testing services, logistical barriers, social stigma, and fragmented healthcare systems. Nevertheless, there is cause for optimism as emerging technologies and innovations hold promise for enhancing EID programs and overcoming existing challenges. Point-of-care testing devices, dried blood spot sampling, nucleic acid amplification tests, telemedicine, mobile health interventions, and electronic medical record systems offer new opportunities to improve the accessibility, accuracy, and efficiency of EID services. By leveraging these technologies and innovations, we can strengthen EID programs, expand access to testing services, and improve outcomes for HIV-infected infants.

## References

1. Shrivastava R, Fonjungo PN, Kebede Y, Bhimaraj R, Zavahir S, Mwangi C, Gadde R, Alexander H, Riley PL, Kim A, Nkengasong JN. Role of public-private partnerships in achieving UNAIDS HIV treatment targets. *BMC health services research*. 2019; 19:1-10.
2. Kiyaga C, Narayan V, McConnell I, Elyanu P, Kisaakye LN, Joseph E, Kekitiinwa A, Grosz J. Uganda's "EID Systems Strengthening" model produces significant gains in testing, linkage, and retention of HIV-exposed and infected infants: an impact evaluation. *Plos one*. 2021;16(2): e0246546.
3. Abrams EJ, Strasser S. 90-90-90—Charting a steady course to end the paediatric HIV epidemic. *Journal of the International AIDS Society*. 2015; 18:20296.
4. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
5. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
6. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf).

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. *Elite Journal of Health Science*, 2023; 1(1):1-11



7. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
8. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
9. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
10. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
11. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
12. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
13. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
14. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.  
[https://www.academia.edu/download/38320140/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
15. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
16. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2016.03.10.009)
17. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
18. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanjo CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA)

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. *Elite Journal of Health Science*, 2023; 1(1):1-11

and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.  
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://epjournals.com/journals/EJHS/links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).

19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.  
[https://www.academia.edu/download/38320159/Obeagu\\_Emanuel\\_Ifeanyi3\\_et\\_al.IJC\\_RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).
20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.  
[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://epjournals.com/journals/EJHS/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
23. Obeagu EI, Ameorpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.  
[links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://epjournals.com/journals/EJHS/links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf).
24. Obeagu EI, Scott GY, Ameorpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
25. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022;29-34.
26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
27. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.  
[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-](https://epjournals.com/journals/EJHS/links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-)

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. Elite Journal of Health Science, 2023; 1(1):1-11

[based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](#).

28. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](#) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](#)
29. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](#) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](#).
30. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](#) [https://www.academia.edu/download/54317126/Haematological\\_indices\\_of\\_malaria\\_patients\\_coinfectd\\_with\\_HIV.pdf](#)
31. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
32. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137](#) [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](#).
33. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
34. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. [http://research.sdpublishers.net/id/eprint/2819/](#).
35. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
36. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. Elite Journal of Health Science, 2023; 1(1):1-11



- journal of Medicine and Health Sciences. 2022;2(3):6-15.  
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
37. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
  38. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.  
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.wjpr.in/links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
  39. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
  40. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: [10.22192/ijcrps.2019.06.12.004](https://doi.org/10.22192/ijcrps.2019.06.12.004)  
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcrps.com/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
  41. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
  42. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
  43. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910.  
[https://www.academia.edu/download/38320134/Obeagu\\_Emanuel\\_Ifeanyi\\_and\\_Obeagu\\_Getrude\\_Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
  44. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
  45. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.  
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. *Elite Journal of Health Science*, 2023; 1(1):1-11

46. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
47. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharmacy Research.* 2014; 391:186-189.
48. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
49. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
50. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemima MC, Okpomesine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.
51. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
52. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
53. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).
54. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
55. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
56. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
57. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
58. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore).* 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.

**Citation:** Obeagu EI, Obeagu GU. Early Infant Diagnosis: A Crucial Step in Halting HIV Transmission. *Elite Journal of Health Science*, 2023; 1(1):1-11

59. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46):e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
60. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
61. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
62. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
63. Katoba J, Kuupiel D, Mashamba-Thompson TP. Toward improving accessibility of point-of-care diagnostic services for maternal and child health in low-and middle-income countries. *Point of care*. 2019;18(1):17-25.
64. Sallam M, Alabbadi AM, Abdel-Razeq S, Battah K, Malkawi L, Al-Abbadi MA, Mahafzah A. HIV knowledge and stigmatizing attitude towards people living with HIV/AIDS among medical students in Jordan. *International Journal of Environmental Research and Public Health*. 2022;19(2):745.
65. Nayak S, Blumenfeld NR, Laksanasopin T, Sia SK. Point-of-care diagnostics: recent developments in a connected age. *Analytical chemistry*. 2017;89(1):102-123.
66. Kang T, Lu J, Yu T, Long Y, Liu G. Advances in nucleic acid amplification techniques (NAATs): COVID-19 point-of-care diagnostics as an example. *Biosensors and Bioelectronics*. 2022; 206:114109.